Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation

Transplant International

Volumn 28, Issue 2, 2015, Pages 255-258

  Delabaudière, Cyrielle ^a   Lavayssière, Laurence ^a   Dörr, Gaëlle ^a   Muscari, Fabrice ^a,b   Danjoux, Marie ^c   Sallusto, Federico ^a   Peron, Jean Marie ^b,c   Bureau, Christophe ^b,c   Rostaing, Lionel ^a,b,c   Izopet, Jacques ^b,c   Kamar, Nassim ^a,b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU PURPAN   (France)

Author keywords

fibrosing cholestatic hepatitis; hepatitis C virus; kidney transplantation; liver transplantation; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BASILIXIMAB; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; MYCOPHENOLIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; STEROID; TACROLIMUS; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG COMBINATION; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; URIDINE PHOSPHATE;

AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHOLESTATIC HEPATITIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERANCE; FATIGUE; FIBROSING CHOLESTATIC HEPATITIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; JAUNDICE; KIDNEY GRAFT REJECTION; KIDNEY LIVER TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; MORNING DOSAGE; PRIORITY JOURNAL; STEROID THERAPY; VIRAL CLEARANCE; WEIGHT REDUCTION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; DRUG COMBINATION; HEPATITIS C; RECURRENT DISEASE;

AGED; ANTIVIRAL AGENTS; DRUG COMBINATIONS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 84920872530     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12428     Document Type: Article

References (14)

1. Satapathy SK, Sclair S, Fiel MI, Del Rio Martin J, Schiano T,. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. Hepatol Res 2011; 41: 328.
2. Gopal DV, Rosen HR,. Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite. Liver Transpl 2003; 9: 348.
3. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34.
4. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878.
5. Osinusi A, Meissner EG, Lee YJ, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804.
6. Pawlotsky JM,. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176.
7. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M,. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053.
8. Fontana RJ, Hughes EA, Bifano M, et al,. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601.
9. Kim B, Trivedi A, Thung SN, Grewal P,. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Semin Liver Dis 2014; 34: 108.
10. Al Nahdi N, Ford JA, Greanya ED, et al,. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol 2013; 12: 156.
11. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D,. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426.
12. Pageaux GP, Hilleret MN, Garrigues V, et al,. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int 2009; 22: 562.
13. Aljumah AA, Saeed MA, Al Flaiw AI, et al,. Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. World J Gastroenterol 2012; 18: 55.
14. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M,. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007; 41: 216.